In the current approach we analysed the AML targeting potential of an innovative biohybrid consisting of the tumor-associated peptide somatostatin and the photosensitizer ruthenium using molecularly and cytogenetically fully annotated primary AML patient samples as targets. This evidence concerns the gene SST and neoplasm.